Agenus Inc Revenue Growth Rates (AGEN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Agenus Inc  (NASDAQ: AGEN)
 

AGEN's Revenue Growth by Quarter and Year

Agenus Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/AGEN/growth
https://api.csimarket.com/api/v1/companies/AGEN/fundamentals
https://api.csimarket.com/api/v1/companies/AGEN/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
AGEN Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 31.49
2nd Quarter June 34.52
1st Quarter March 33.74
FY 99.75

AGENs Annual Revenue
Agenus Inc's Revenue in the fiscal year 2025 $ 114.20 millions
Agenus Inc's Revenue in the fiscal year 2024 $ 103.46 millions
Agenus Inc's Revenue in the fiscal year 2023 $ 156.31 millions
Agenus Inc's Revenue in the fiscal year 2022 $ 98.02 millions
Agenus Inc's Revenue in the fiscal year 2021 $ 295.67 millions




AGEN Revenue third quarter 2026 Y/Y Growth Comment
Agenus Inc reported Revenue growth of 4.13% year on year in the third quarter 2026, to $ 31.49 millions, this is lower than Agenus Inc's recent average Revenue rise of 85.66%.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 38 other companies have achieved higher Revenue growth. While Agenus Inc' s Revenue increase of 4.13% ranks overall at the positon no. 2364 in the third quarter 2026.


AGEN Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 4.13 %
2nd Quarter June 34.37 %
1st Quarter March 40.17 %
FY   -

Financial Statements
Agenus Inc's third quarter 2026 Revenue $ 31.49 millions AGEN's Income Statement
Agenus Inc's third quarter 2025 Revenue $ 30.24 millions Quarterly AGEN's Income Statement


AGEN Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -8.78 %
2nd Quarter June 2.31 %
1st Quarter March -1.35 %
FY (Year on Year)   -


Back to AGEN Growth rate Comparisons >> Back to AGEN Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #39
Healthcare Sector #342
Overall #2364

Revenue Y/Y Growth Statistics
High Average Low
555.23 % 85.66 % -80.92 %
(Mar 31 2019)   (Dec 31 2013)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #39
Healthcare Sector #342
Overall #2364
Revenue Y/Y Growth Statistics
High Average Low
555.23 % 85.66 % -80.92 %
(Mar 31 2019)   (Dec 31 2013)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Agenus Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2257.45 % 115.07 % -95.31 %
(Sep 30 2021)  


AGEN's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Agenus Inc disclosed drop in Revenue from the second quarter by -8.78% to $ 31.49 millions, from $ 34.52 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 25 other companies have achieved higher Revenue quarter on quarter growth. While Agenus Inc's Revenue growth quarter on quarter, overall rank is 1420.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #26
Healthcare Sector #195
Overall #1420
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #26
Healthcare Sector #195
Overall #1420
Revenue Q/Q Growth Statistics
High Average Low
2257.45 % 115.07 % -95.31 %
(Sep 30 2021)  


AGEN's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Agenus Inc disclosed drop in Revenue from the second quarter by -8.78% to $ 31.49 millions, from $ 34.52 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 25 other companies have achieved higher Revenue quarter on quarter growth. While Agenus Inc's Revenue growth quarter on quarter, overall rank is 1420.


Agenus Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 132.69
Y / Y Revenue Growth (TTM) 30.47 %
Year on Year Revenue Growth Overall Ranking # 3501
Seqeuential Revenue Change (TTM) 7.13 %
Seq. Revenue Growth (TTM) Overall Ranking # 2410


Cumulative Revenue growth Comment
Although Agenus Inc's Annual Revenue growth year on year were below company's average 85.66% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 30.47% year on year, from 24.46% in Mar 31 2026.

In the Healthcare sector 477 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2493 to 3501.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 39
Healthcare Sector # 478
Overall # 3501

Revenue TTM Y/Y Growth Statistics
High Average Low
555.23 %
 85.66 %
-80.92 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 39
Sector # 346
S&P 500 # 2410
Cumulative Revenue growth Comment
Although Agenus Inc's Annual Revenue growth year on year were below company's average 85.66% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 30.47% year on year, from 24.46% in Mar 31 2026.

In the Healthcare sector 477 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2493 to 3501.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 39
Healthcare Sector # 478
Overall # 3501

Revenue TTM Y/Y Growth Statistics
High Average Low
555.23 %
85.66 %
-80.92 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 39
Sector # 346
S&P 500 # 2410




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AGEN's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Addus Homecare Corp7.19%$ 7.193 millions
Pacific Biosciences Of California Inc 7.03%$ 7.026 millions
Bristol myers Squibb Company6.93%$ 6.930 millions
Labcorp Holdings Inc 6.92%$ 6.917 millions
Gilead Sciences Inc 6.83%$ 6.835 millions
Arcturus Therapeutics Holdings Inc 6.68%$ 6.682 millions
National Healthcare Corp6.61%$ 6.614 millions
Tenet Healthcare Corp6.47%$ 6.466 millions
Phibro Animal Health Corporation6.32%$ 6.320 millions
Mettler toledo International Inc 6.27%$ 6.273 millions
Agilon Health Inc 5.86%$ 5.864 millions
Johnson and Johnson5.86%$ 5.860 millions
Stoke Therapeutics Inc 5.86%$ 5.860 millions
Genedx Holdings Corp 5.64%$ 5.642 millions
Adma Biologics Inc 5.59%$ 5.595 millions
Innoviva Inc 5.55%$ 5.551 millions
Universal Health Services Inc 5.30%$ 5.297 millions
Acadia Healthcare Company Inc 5.14%$ 5.136 millions
Lumexa Imaging Holdings Inc 5.03%$ 5.032 millions
Bio techne Corp4.75%$ 4.753 millions
Merck and Co Inc 4.68%$ 4.683 millions
Davita Inc 4.62%$ 4.617 millions
Sotera Health Company4.61%$ 4.613 millions
Avantor Inc 4.59%$ 4.588 millions
Icu Medical Inc4.39%$ 4.388 millions
Illumina Inc 4.15%$ 4.151 millions
Agenus Inc4.14%$ 4.144 millions
United Therapeutics Corporation4.13%$ 4.128 millions
Option Care Health Inc 4.09%$ 4.086 millions
Henry Schein Inc 3.95%$ 3.953 millions


About Agenus Inc Revenue Growth Rates (AGEN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Agenus Inc (CIK 1098972).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-449984
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Agenus Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.